scispace - formally typeset
I

Irina Lambertz

Researcher at Ghent University

Publications -  11
Citations -  940

Irina Lambertz is an academic researcher from Ghent University. The author has contributed to research in topics: Neuroblastoma & Cancer. The author has an hindex of 8, co-authored 11 publications receiving 855 citations.

Papers
More filters
Journal ArticleDOI

The need for transparency and good practices in the qPCR literature

Stephen A. Bustin, +83 more
- 01 Nov 2013 - 
TL;DR: Two surveys of over 1,700 publications whose authors use quantitative real-time PCR (qPCR) reveal a lack of transparent and comprehensive reporting of essential technical information.
Journal ArticleDOI

Monoallelic but not biallelic loss of Dicer1 promotes tumorigenesis in vivo.

TL;DR: It is shown that although monoallelic loss of Dicer1 does not affect normal retinal development, it dramatically accelerates tumor formation on a retinoblastoma-sensitized background and concludes that Dicer 1 functions as a haploinsufficient tumor suppressor.
Journal ArticleDOI

An Illegitimate microRNA Target Site within the 3′ UTR of MDM4 Affects Ovarian Cancer Progression and Chemosensitivity

TL;DR: It is concluded that acquisition of an illegitimate miR-191 target site causes downregulation of MDM4 expression, thereby significantly delaying ovarian carcinoma progression and tumor-related death and appear to be, at least partly, independent of p53.
Journal ArticleDOI

Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma.

TL;DR: Targeted disruption of the p53-MDM2 interaction by the small-molecule MDM2 antagonist nutlin-3 stabilizes p53 and selectively activates the p 53 pathway in neuroblastoma cells with wild-type p53, resulting in a pronounced antiproliferative and cytotoxic effect through induction of G(1) cell cycle arrest and apoptosis.
Journal ArticleDOI

Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.

TL;DR: Nutlin-3 activates the p53 pathway and suppresses tumor growth and reduction in the extent of metastatic disease in this model system of chemoresistant neuroblastoma, provided that wild-type p53 is present.